colchicine/fever

The link is saved to the clipboard

Choose sort type

Page 1 from 1274 results

Novel therapeutics for the treatment of familial Mediterranean fever: from colchicine to biologics.

Only registered users can translate articles

Familial Mediterranean fever (FMF), an inherited autosomal recessive disorder, is characterized by sporadic, paroxysmal attacks of fever and serosal inflammation, lasting 1-3 days. Patients may develop renal amyloidosis, arthritis, serositis, and skin and oral lesions. Diagnosis is based on clinical

Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever.

Only registered users can translate articles

BACKGROUND This open-label pilot study aimed to investigate the efficacy of canakinumab in colchicine-resistant familial Mediterranean fever (FMF) patients. METHODS Patients with one or more attacks in a month in the preceding 3 months despite colchicine were eligible to enter a 30-day run-in

Efficacy of colchicine therapy in amyloid nephropathy of familial Mediterranean fever.

Only registered users can translate articles

The aim of this study was to investigate the effect of colchicine therapy on the outcome of amyloid nephropathy of familial Mediterranean fever (FMF) in childhood. The diagnosis of amyloidosis type AA was confirmed by renal biopsy in 38 patients. During a mean follow-up period of 30.5 months (range

Effect of colchicine on immunoregulatory abnormalities in familial Mediterranean fever.

Only registered users can translate articles

The effect of colchicine on immunoregulatory T lymphocytes in children with familial Mediterranean fever (FMF) was studied. Concanavalin A (Con A)-induced suppressor cell function was significantly (P less than 0.0001) decreased in five untreated FMF patients (15 +/- 3%, mean +/- s.e.) as compared

Correction of a suppressor cell deficiency in familial Mediterranean fever by colchicine.

Only registered users can translate articles

We have previously reported a suppressor cell deficiency in four patients with familial Mediterranean fever (FMF). Since colchicine prevents FMF attacks, we tested the effect of colchicine (1 mg twice daily) on the suppressor cell function in three of these FMF patients. Proliferation of

Colchicine enhances intestinal permeability in patients with familial Mediterranean fever.

Only registered users can translate articles

OBJECTIVE Colchicine therapy is complicated by frequent gastrointestinal adverse effects. METHODS We compared intestinal permeability in 21 patients with familial Mediterranean fever on long-standing colchicine therapy (mean 5.8 years) and significant gastrointestinal complaints and 12 untreated

Gastrointestinal effects of long-term colchicine therapy in patients with recurrent polyserositis (familial mediterranean fever).

Only registered users can translate articles

Twelve patients with recurrent polyserositis (RP, familial Mediterranean fever) on colchicine prophylaxis (1.0-2.0 mg daily) for three years or more were evaluated for the presence of gastrointestinal effects possibly attributable to the drug. Two patients had bulky stools, two others had transient

Intravenous colchicine for treatment of patients with familial Mediterranean fever unresponsive to oral colchicine.

Only registered users can translate articles

OBJECTIVE To evaluate the efficacy and safety of weekly intravenous (IV) colchicine, in addition to oral colchicine therapy, in a subset of patients with familial Mediterranean fever (FMF) unresponsive to oral colchicine prophylaxis. METHODS Thirteen patients with frequent FMF attacks, despite oral

Efficacy and safety of long-term treatment with intravenous colchicine for familial Mediterranean fever (FMF) refractory to oral colchicine.

Only registered users can translate articles

Colchicine is the mainstay of treatment for familial Mediterranean fever (FMF). Intravenous (IV) colchicine, administered over several months, has been shown to be effective for FMF patients unresponsive to oral colchicine. The objective of this study was to evaluate the efficacy and safety of

Colchicine concentration in leukocytes of patients with familial Mediterranean fever.

Only registered users can translate articles

Free and total plasma, granulocyte and mononuclear cell colchicine concentrations were measured by radioimmunoassay in 30 patients with familial Mediterranean fever treated with colchicine 0.5 to 2 mg day-1. Colchicine concentrations showed a large intersubject variability in plasma (0.13-1.75 ng

Long-term colchicine therapy of familial Mediterranean fever.

Only registered users can translate articles

Familial Mediterranean fever is a disorder characterized by recurrent fever and polyserositis. Continuous prophylactic colchicine therapy has been effective in suppressing attacks in affected adults. From 30 children with FMF, 14 were selected for colchicine therapy. Eight children continued

Can colchicine response be predicted in familial Mediterranean fever patients?

Only registered users can translate articles

OBJECTIVE The aims of this study were to explore whether the demographic and clinical features of paediatric familial Mediterranean fever (FMF) patients with different colchicine response vary or not and to determine whether colchicine response can be predicted in FMF patients. METHODS Files of

Colchicine in breast milk of patients with familial Mediterranean fever.

Only registered users can translate articles

OBJECTIVE To clarify whether colchicine is excreted in breast milk, and to compare its concentrations in the serum and breast milk of lactating women who have familial Mediterranean fever (FMF). METHODS Using a specific radioimmunoassay, we determined colchicine concentrations in the serum and

Colchicine in tear fluid of treated patients with familial Mediterranean fever.

Only registered users can translate articles

OBJECTIVE The study aimed to determine whether detectable concentrations of colchicine are present in the tear fluid of treated patients with familial Mediterranean fever (FMF) and thus demonstrate a possible route by which colchicine reaches the corneal surface. METHODS Tear fluid samples (50-100

Colchicine kinetics in patients with familial Mediterranean fever.

Only registered users can translate articles

Serum colchicine levels were determined by radioimmunoassay after a 1-mg bolus injected intravenously in 4 patients with familial Mediterranean fever and in 6 normal subjects. Mean elimination half-life (t1/2) (+/- SEM) was 157 +/- 20 min in the patients and 65 +/- 15 min in the normal subjects (p

Join our facebook page

Herbal & Natural Medicine

The most complete medicinal herbs database backed by science

Works in 55 languages
Herbal cures backed by science
Herbs recognition by image
Interactive GPS map - tag herbs on location (coming soon)
Read scientific publications related to your search
Search medicinal herbs by their effects
Organize your interests and stay up do date with the news research, clinical trials and patents

Type a symptom or a disease and read about herbs that might help, type a herb and see diseases and symptoms it is used against.
*All information is based on published scientific research